BioLife Solutions, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
BioLife Solutions, Inc. (BLFS) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2022-11-09
- BioLife Solutions, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2022-09-30 was 0.00 shares.
- BioLife Solutions, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2022-06-30 was 0.00 shares.
- BioLife Solutions, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-09-30 was 0.00 shares.
- BioLife Solutions, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-06-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|
| 2022-09-30 | 0.00 shares 10-Q · filed 2022-11-09 | 0.00 shares 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 0.00 shares 10-Q · filed 2022-08-09 | 0.00 shares 10-Q · filed 2022-08-09 | |
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-09 | 24.34K shares 10-Q · filed 2022-11-09 | |
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-09 | 36.71K shares 10-Q · filed 2022-08-09 | |
| 2020-09-30 | 0.00 shares 10-Q · filed 2020-11-09 | 1.95M shares 10-Q · filed 2020-11-09 | |
| 2019-09-30 | 3.05M shares 10-Q · filed 2020-11-09 | 0.00 shares 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |